3-iodo-2,2-dimethylpropionate methyl ester | 150349-54-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-iodo-2,2-dimethylpropionate methyl ester
• 英文别名: methyl 3-iodo-2,2-dimethylpropanoate；methyl 2,2-dimethyl-3-iodo-propanoate
• CAS: 150349-54-5
• 化学式: C₆H₁₁IO₂
• 分子量: 242.057
• InChiKey: CMXCNXJZKXRQNL-UHFFFAOYSA-N

物化性质

• 沸点：
  208.6±13.0 °C(Predicted)
• 密度：
  1.614±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-iodo-2,2-dimethylpropionate methyl ester 在 四(三苯基膦)钯 、 oxone 、 sodium hydroxide 作用下， 以 甲醇 、 N,N-二甲基乙酰胺 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 21.83h， 生成 3-(4-{5-[5-(4-methoxy-phenyl)-[1,3,4]oxadiazol-2-yl]-1H-benzoimidazol-2-yl}-3,5-dimethyl-phenyl)-2,2-dimethyl-propionic acid
  参考文献：
  名称：

  Discovery of an Orally Bioavailable Benzimidazole Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor That Suppresses Body Weight Gain in Diet-Induced Obese Dogs and Postprandial Triglycerides in Humans

  摘要：

  Modification of a gut restricted class of benziMidazole DGAT1 inhibitor 1 led to 9 with good oral bioavailability. The key structural changes to 1 include bioisosteric replacement of the amide with oxadiazole and a,a-dimethylation of the carboxylic acid, improving DGAT1 potency and gut permeability. Since DGAT1 is expressed in the small intestine, both 1,and 9 can suppress postprandial triglycerides during acute oral lipid challenges in rats and dogs. Interestingly, only 9 was found to be effective in suppressing body weight gain relative to control in a diet-induced obese dog model, suggesting the importance of systemic inhibition of DGAT1 for body weight control. 9 has advanced to clinical investigation and successfully suppr8sed postprandial triglycerides during an acute meal challenge in humans.

  DOI：

  10.1021/acs.jmedchem.7b00173

文献信息

• SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES
  申请人：Bouey Edith

  公开号：US20100004159A1

  公开（公告）日：2010-01-07

  The present invention relates to polysubstituted imidazolone derivatives, to the pharmaceutical compositions comprising them and to the therapeutic uses thereof in the human and animal health fields. The present invention also relates to a process for preparing these derivatives.

  本发明涉及多取代咪唑酮衍生物，包括它们的药物组合物以及在人类和动物健康领域中的治疗用途。本发明还涉及一种制备这些衍生物的方法。
• Doxepin analogs and methods of use thereof
  申请人：Edgar M. Dale

  公开号：US20050143348A1

  公开（公告）日：2005-06-30

  The invention relates to novel antihistamines and methods of modulating sleep by administering a doxepin analog or a pharmaceutically effective salt thereof.

  这项发明涉及新型抗组胺药物和通过给予多塞平类似物或其药效盐来调节睡眠的方法。
• [EN] OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE ET D'INDOLE SUBSTITUÉS PAR DE L'OXADIAZOLE ET OXAZOLE COMME INHIBITEURS DE DGAT1
  申请人：NOVARTIS AG

  公开号：WO2009040410A1

  公开（公告）日：2009-04-02

  The present invention provides oxadiazolyl- substituted benzimidazole- and idole-derivates that are useful for treating conditions or disorders associated with DGAT1 activity in animals, particularly humans.

  本发明提供了一种对氧代二唑基取代的苯并咪唑和吲哚衍生物，用于治疗与动物，特别是人类的DGAT1活性相关的疾病或疾病。
• Efficient and convenient preparation of 3-aryl-2,2-dimethylpropanoates via Negishi coupling
  作者：Young-Shin Kwak、Aaron D. Kanter、Bing Wang、Yugang Liu

  DOI：10.1039/b902779c

  日期：——

  An efficient and convenient Negishi coupling protocol was developed for the preparation of 3-aryl-2,2-dimethylpropanoates providing easy access to key pharmaceutical intermediates that often require multi-step synthesis using conventional enolate chemistry.

  开发了一种高效便捷的Negishi偶联方案，用于制备3-芳基-2,2-二甲基丙酸酯，从而可以轻松获得关键药物中间体，而这些中间体通常需要使用常规烯醇酸酯化学进行多步合成。
• ORGANIC COMPOUNDS
  申请人：Kwak Young-Shin

  公开号：US20110077277A1

  公开（公告）日：2011-03-31

  The present invention provides compounds of the following structure; A-Q-B—C-D that are useful for treating conditions or disorders associated with DGAT1 activity in animals, particularly humans.

  本发明提供了以下结构的化合物; A-Q-B-C-D，用于治疗与动物（尤其是人类）中的DGAT1活性相关的病症或疾病。